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Abstract
Background:  Transforming growth factor beta 1 (TGFB1) forms a signaling complex with
transforming growth factor beta receptors 1 and 2 and has been described as both a tumor
suppressor and tumor promoter. Single nucleotide polymorphisms in TGFB1 and a microsatellite in
TGFBR1 have been investigated for association with risk of breast cancer, with conflicting results.
Methods: We examined polymorphisms in the promoter region of the TGFB1 gene as well as the
TGFBR1*6A microsatellite in the Nurses' Health Study cohort.
Results:  No overall associations between the L10P polymorphism of TGFB1 or the TGFBR1
microsatellite were detected. However, we observed an inverse association between the -509 C/
T polymorphism of TGFB1 (p-trend = 0.04), which was stronger and more significant among women
with estrogen receptor positive breast cancer.
Conclusion: Polymorphisms in the promoter region of TGFB1 are not likely to be associated with
large increases in breast cancer risk overall among Caucasian women.
Background
Transforming growth factor beta 1 (TGFB1) can act as a
tumor suppressor by mediating growth arrest via the CDK
inhibitors p15INK4B [1] and/or p21CIP1 [2,3] and by inhib-
iting the expression of c-Myc [4], CDK4 [5,6], and
CDC25A [7,8]. Paradoxically, tumor cells have been
shown to overexpress TGFB1 [9,10]. This overexpression
is thought to induce angiogenesis [11-15] as well as
expression of endothelial growth factor, leading to cell
proliferation and migration [16,17] and allowing tumor
cells to escape from the immune system [18-20].
Polymorphisms (-509 and L10P) in the TGFB1 gene have
been associated with increased levels of TGFB1 in the
serum [21]. The L10P polymorphism has been shown to
increase the secretion of TGFB1 in vitro [22]. However,
studies examining the association between TGFB1 poly-
morphisms and breast cancer risk have failed to yield a
clear picture.
In a prospective cohort of older women, Ziv et al. [23]
found a lower risk of breast cancer associated with the C/
C genotype as compared to the T/T genotype at the T29C
(L10P) SNP (hazard ratio 0.42, 95% CI 0.22 – 0.79). In a
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population-based case-control study, Dunning et al. [22]
found an increase in risk of invasive breast cancer associ-
ated with this SNP (Pro/Pro genotype compared to Leu
carrier; OR 1.21, 95% CI 1.05 – 1.37). Two other studies
found no association between this SNP and breast cancer
risk [24,25]. A recent pooled analysis of case-control stud-
ies found a moderate increase in breast cancer risk associ-
ated with this polymorphism (per variant allele OR 1.08,
95% CI 1.02 – 1.14) [26].
Transforming growth factor beta receptor type I (TGFBR1)
is a serine-threonine protein kinase. Though it cannot
directly bind TGFB1, it is recruited into a heteromeric
complex with the TGFB type II receptor that is able to bind
TGFB1 [27]. The signaling complex that results has the
two TGFBR1 molecules necessary for the antimitogenic
effects of TGFB1 [28]. One common polymorphism in
TGFBR1 is a microsatellite in the coding sequence of the
gene, corresponding to a variable stretch of alanine resi-
due. In vitro studies have shown that TGFBR1*6A (the
allele of this microsatellite corresponding to 6 alanine res-
idues) does not respond as well as the normal 9-alanine
TGFBR1 to the growth inhibitory signals of TGFB1
[29,30].
The findings of several studies examining the relationship
between TGFBR1*6A and cancer have been inconsistent.
A meta-analysis of 12 of these studies showed that carry-
ing at least one copy of the 6A allele increased the risk of
cancer overall (OR 1.24, 95% CI 1.10 – 1.40) and of
breast cancer specifically (1,420 cases and 3,451 controls,
OR 1.38, 95% CI 1.14 – 1.67) [31]. We genotyped this
microsatellite in the Nurses' Health Study breast cancer
nested case-control samples, the largest single study
(1,196 cases and 1,677 controls genotyped successfully)
analyzed to date, in order to better understand its relation-
ship to breast cancer.
Kaklamani et al. hypothesized that different combina-
tions of the TGFB1 L10P polymorphism and the TGFBR1
microsatellite would produce varying levels of TGFB1 sig-
naling [32]. The authors observed that altered TGFB1 sig-
naling levels altered breast cancer risk (intermediate vs.
high signalers OR 1.27, 95% CI 0.93 – 1.74; low vs. high
signalers OR 1.69, 95% CI 1.08 – 2.66). We therefore
examined this interaction in our study as well.
Methods
The Nurses' Health Study was established in 1976, when
121,700 female registered nurses between the ages of 30
and 55 completed a self-administered questionnaire on
their medical histories and baseline health related expo-
sures. Updated information has been obtained by ques-
tionnaires every 2 years. Incident breast cancers were
identified by self-report and confirmed by medical record
review. Between 1989 and 1990, blood samples were col-
lected from 32,826 of the cohort members. Subsequent
follow-up has been greater than 98% for this subcohort.
Eligible cases in this study consisted of women with path-
ologically confirmed incident breast cancer from the sub-
cohort who gave a blood specimen. Cases with a diagnosis
anytime after blood collection up to 1 June 2000 with no
previously diagnosed cancer except for nonmelanoma
skin cancer were included. One or two controls were ran-
domly selected among women who gave a blood sample
and were free of diagnosed cancer (excluding non-
melanoma skin cancer) up to and including the question-
naire cycle in which the case was diagnosed. Controls
were matched to cases on year of birth, menopausal sta-
tus, postmenopausal hormone use at blood collection,
month of blood return, time of day of blood collection,
and fasting status at blood draw. The nested case-control
study consists of 1,311 incident breast cancer cases and
1,760 matched controls.
The -509 (rs1800469) and L10P (rs1982073) single
nucleotide polymorphisms were genotyped using cus-
tom-designed 5' endonuclease assays (Taqman, Applied
Biosystems, Foster City, CA; primer and probe sequences
available upon request). The TGFBR1*6A microsatellite
was genotyped using gel electrophoresis of PCR products.
Quality control (QC) replicate samples were included on
study plates, with laboratory personnel blinded to both
QC and case or control status of the samples. All statistical
analyses were carried out using SAS V9.1 (SAS Institute,
Cary, NC), with the exception of polytomous regressions
[33] and meta-analyses (rmeta package in R). The
TGFBR1*6A meta analyses were carried out using prior
reports of genotyping results of this polymorphism in
breast cancer cases and controls. Power calculations were
carried out using Quanto [34]. This study was approved
by the IRB of the Brigham and Women's Hospital.
Results
We did not detect any deviation from Hardy-Weinberg
equilibrium at either SNP (p = 0.59 for -509 and 0.49 for
L10P in controls). Risk assessments using conditional
logistic regression models were similar to unconditional
analyses, therefore we will report only the unconditional
analyses to increase power. Though no overall association
was found between L10P and breast cancer risk, a margin-
ally significant an inverse association between the -509
SNP and breast cancer risk was detected (Table 1). This
association was limited to women diagnosed with estro-
gen receptor (ER) positive tumors (p-heterogeneity in risk
between ER+ and ER- breast cancer = 0.002) (Table 2).
Compared to controls and using the C/C genotype as a
reference, women heterozygous at -509 had an 18%
decrease in risk of ER+ breast cancer (OR 0.82, 95% CI
0.67 – 1.00), women homozygous for the T allele had aBMC Cancer 2007, 7:175 http://www.biomedcentral.com/1471-2407/7/175
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38% decrease in risk (OR 0.62, 95% CI 0.42 – 0.90), and
there was a highly significant trend in decreased risk
across these two genotypes (p = 0.04 for L10P and p =
0.005 for -509). The association was similar among pro-
gesterone receptor (PR) positive tumors. No difference in
risk was observed upon stratification by menopausal sta-
tus at diagnosis, body mass index (BMI <30/30+), or post-
menopausal hormone (PMH) use (ever/never) for either
SNP.
The genotype frequencies of the TGFBR1 alanine micros-
atellite (TGFBR1*6A) were similar in cases and controls
(Table 3); since there were so few rare variants (<1%),
these were removed from the analyses. Again, no devia-
tion from Hardy-Weinberg equilibrium was detected
among controls (p = 0.65). Following the classification of
high, intermediate, and low signalers proposed by Kakla-
mani et al., the L10P polymorphism in TGFB1 and alleles
of the TGFBR1*6A microsatellite were combined. No dif-
ference in risk was observed among the high, intermedi-
ate, and low signaling types (Table 4), and no difference
in risk was observed upon stratifying the cases by estrogen
receptor status of their tumors (data not shown). In order
to clarify previous reports of association between this pol-
ymorphism and breast cancer risk, we have also per-
formed a meta-analysis including our results with
previously reported genotyping results of this polymor-
phism in breast cancer cases and controls. We have sepa-
rated out all the participating populations (i.e. the two
populations represented in Jin et al. [35], genotypes
attributed to Reiss in [31], in addition the genotypes
attributed to Offitt in [31] were removed, as they were
included by Kaklamani et al. [32]) in order to more clearly
evaluate and display the data. The summary odds ratio
was 1.10 (95% CI 0.89 – 1.38) from the random effects
model (Fig. 1), however, there was evidence of significant
heterogeneity in risk estimates (p-heterogeneity < 0.01).
Discussion
Although the TGFBR1*6A polymorphism has been asso-
ciated with breast cancer risk in a meta-analysis (with a
total of 1,420 cases and 3,451 controls), we did not see
any evidence of a relationship between this microsatellite
and breast cancer in our large nested case-control study.
Our study has 80% power to detect a log-additive per
allele odds ratio of 1.27 at the alpha = 0.05 level. We have
added our results, and to prior genotyping reports
[31,32,35-39]. This new meta-analysis consists of 3,459
Table 2: Association between TGFB1 SNPs and breast cancer risk in ER+ breast cancer analyses in the Nurses' Health Study
Genotype Cases (%) Controls (%) OR (95% CI)*
L10L (T/T) 277 (41.3) 613 (37.1) 1.00 (Ref.)
L10P (T/C) 305 (45.5) 797 (48.3) 0.81 (0.66 – 0.99)
P10P (C/C) 89 (13.3) 241 (14.6) 0.79 (0.59 – 1.06)
p-trend = 0.04
-509 C/C 354 (52.4) 786 (47.3) 1.00 (Ref.)
-509 C/T 276 (40.8) 723 (43.5) 0.82 (0.67 – 1.00)
-509 T/T 46 (6.8) 154 (9.3) 0.63 (0.43 – 0.92)
p-trend = 0.005
*Unconditional logistic regression controlled for matching factors, family history of breast cancer, age at menopause, age at menarche, BMI at age 
18, weight gain since age 18, age at first birth/parity, and personal history of benign breast disease
Table 3: Association between the TGFBR1 alanine microsatellite 
and breast cancer risk in the Nurses' Health Study
Genotype Cases (%) Controls (%) OR* (95% CI)
9A/9A 968 (80.9) 1352 (80.6) 1.00 (Ref.)
6A/9A 207 (17.3) 302 (18.0) 0.95 (0.76 – 1.17)
6A/6A 12 (1.0) 19 (1.1) 0.80 (0.37 – 1.73)
Other 9 (0.8) 4 (0.2) ---
*Unconditional logistic regression controlled for matching factors, 
family history of breast cancer, age at menopause, age at menarche, 
BMI at age 18, weight gain since age 18, age at first birth/parity, and 
personal history of benign breast disease
Table 1: Association between TGFB1 SNPs and breast cancer 
risk in the Nurses' Health Study
Genotype Cases (%) Controls (%) OR (95% CI)*
L10L (T/T) 469 (39.6) 613 (37.1) 1.00 (Ref.)
L10P (T/C) 548 (46.2) 797 (48.3) 0.87 (0.74 – 1.04)
P10P (C/C) 168 (14.2) 241 (14.6) 0.92 (0.72 – 1.17)
p-trend = 0.27
-509 C/C 600 (50.2) 786 (47.3) 1.00 (Ref.)
-509 C/T 506 (42.3) 723 (43.5) 0.89 (0.76 – 1.05)
-509 T/T 89 (7.4) 154 (9.3) 0.76 (0.56 – 1.02)
p-trend = 0.04
*Unconditional logistic regression controlled for matching factors, 
family history of breast cancer, age at menopause, age at menarche, 
BMI at age 18, weight gain since age 18, age at first birth/parity, and 
personal history of benign breast diseaseBMC Cancer 2007, 7:175 http://www.biomedcentral.com/1471-2407/7/175
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breast cancer cases and 4,557 controls. While the sum-
mary odds ratio does not show a statistically significant
change in risk associated with this polymorphism, there is
statistically significant heterogeneity in the risk estimates.
One possible explanation of this heterogeneity is varia-
tion in the specificity of genotyping methods used. How-
ever, the most likely explanation for this heterogeneity is
random sampling variation, despite the fact that the stud-
ies presented are all composed of mostly Caucasian pop-
ulations.
Prior studies have shown increases, decreases, or no
change in breast cancer risk associated with the L10P pol-
ymorphism of TGFB1. Recently, the Breast Cancer Associ-
ation Consortium pooled data from case-control studies
examining this polymorphism, including 5,587 breast
cancer cases and 6,863 controls, and found a very moder-
ate per-allele increase in breast cancer risk associated with
this polymorphism (OR 1.08, 95% CI 1.02 – 1.14) [40].
Our study is underpowered to detect such an association,
although the association we observed between this SNP
and breast cancer risk was in the opposite direction. If we
combine our risk estimate for the L10P polymorphism
with those of the Breast Cancer Association Consortium
(BCAC), significant heterogeneity in risk estimates (p-het-
erogeneity = 0.03, random effects model) is observed, and
the summary odds ratio would be 1.02, 95% CI 0.88 –
1.17). It is unlikely that population differences would
explain the heterogeneity between our results and the
BCAC, as in a recent genome wide association scan per-
formed on a subset of the NHS breast cancer cases and
controls >99% of the subjects did not have genetic contri-
butions from populations other than Caucasian [41]. One
possible explanation for this heterogeneity is that the
BCAC is largely composed of prevalent cases, as compared
to only incident cases in the NHS, and therefore case-spe-
cific variables which may effect the association between
this polymorphism and breast cancer risk overall could
have different distributions in the BCAC as compared to
the NHS. More than likely however, this heterogeneity is
due to sampling variation.
Random-effects meta-analysis of TGFBR1*6A under a dominant model Figure 1
Random-effects meta-analysis of TGFBR1*6A under a dominant model.
Table 4: Association between TGFB1 L10P/TGFBR1*6A 
hypothesized signaling levels and breast cancer risk in the 
Nurses' Health Study
Signaling level Cases (%) Controls (%) OR* (95% CI)
High 129 (11.7) 185 (11.8) 1.00 (Ref.)
Intermediate 797 (72.1) 1113 (71.3) 0.97 (0.75 – 1.25)
Low 179 (16.2) 264 (16.9) 0.92 (0.68 – 1.26)
*Unconditional logistic regression controlled for matching factors, 
family history of breast cancer, age at menopause, age at menarche, 
BMI at age 18, weight gain since age 18, age at first birth/parity, and 
personal history of benign breast diseaseBMC Cancer 2007, 7:175 http://www.biomedcentral.com/1471-2407/7/175
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More interesting is our observation that TGFB1 polymor-
phisms are inversely associated with ER+ breast cancers.
TGFB1 colocalizes with ERα in mouse mammary epithe-
lial cells, and there is a higher proportion of ERα-positive
proliferating mammary epithelial cells in mice with only
one copy of the tgfB gene, which therefore have signifi-
cantly lower TGFB1 protein levels [42,43]. This is evi-
dence that TGFB1 may prevent proliferation in ER-
positive breast epithelial cells. The T allele of the -509 SNP
in TGFB1 has been associated with higher levels of
secreted TGFB1 [21]. Our association between this allele
and decreased risk of estrogen receptor positive tumors is
compatible with the hypothesis that increased TGFB1 lev-
els decrease the potential for proliferation in ER+ breast
cells. As these results are not our original hypotheses, our
observation that TGFB1 polymorphisms are inversely
associated with ER+ breast cancers should be considered
hypothesis generating, and needs further replication.
Conclusion
In conclusion, polymorphisms in the promoter region of
TGFB1 are not likely to be associated with large increases
in breast cancer risk overall among Caucasian women.
However, alleles in this region associated with increased
TGFB1 levels may reduce the risk of estrogen receptorpos-
itive breast tumors.
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